Here Are 10 Biotech People To Follow On Twitter

Do you think we're in a biotech bubble? Find out how you can join the experts in a discussion about the most profitable investments in the biotechnology and pharmaceutical sectors here.

Let's be honest: biotech is hot right now. 

But investors might be wondering where to find more information about such a volatile sector. So, Benzinga has put together a list of scientists, analysts, investors and others in the biotechnology space to add to your Twitter feed to stay up-to-date on the hottest stocks in the sector: 

Adam Feuerstein, Senior Columnist at TheStreet (@adamfeuerstein)

Arguably one of the most notable voices in biotechnology on Twitter, Adam Feuerstein tweets everything from his own articles and reports to breaking news and other standalone facts about biotech companies. He’s also very active in responding to other Twitter users. Feuerstein will answer your questions live on Benzinga’s #BestOfBiotech show this Friday. Learn more about it here.

. @BioRunUp $ADXS move higher is reaction to this week’s $ADRO IPO. Valuation gap.

— Adam Feuerstein (@adamfeuerstein) April 13, 2015

Andy Biotech, Biotech Investor (@AndyBiotech)

Andy Biotech also uses the title “recovering scientist” in his profile’s bio. Follow this account for active tweeting that includes charts, graphs and other useful information.

$AZN down 3%+ (~$3B in MC) on cautious languages in FDA AdComm BD of saxagliptin CVOT results. pic.twitter.com/ei7HutwwO1

— Andy Biotech (@AndyBiotech) April 10, 2015

Alfredo Fontanini, Associate Professor in Neurobiology & Behavior at Stony Brook University (@AF_biotech)

Alfredo Fontanini received his PhD in neuroscience more than a decade ago and has published numerous pieces of academic research throughout his career. His tweets are thoughtful and honest.

I own $CYNAF because IMO sublingual strips are convenient, safe and effective (even if slower and less effective than subq apo)

— Alfredo Fontanini (@AF_biotech) April 10, 2015

Don Shimoda, Biotech Investor (@zDonShimoda)

Follow biotech investor Don Shimoda for plenty of charts, interaction and analytical discussion regarding biotech stocks and risk/reward.

Top 10 Bio Performance YTD ( $TRIL moves into #4 spot +170%) pic.twitter.com/ctEkUQvYhp

— Don Shimoda (@zDonShimoda) April 4, 2015

Christian tharp, Chartered Market Technician and Stock Coach (@cmtstockcoach)

Christian Tharp is a sharp technical analyst who has taught more than 2,500 students across the globe about trading and investing. Follow his Twitter account for links to market content around the web. Tharp will share his trading strategies and answer any biotech questions you have for free. Find out how.

Biotechs could be the early warning for stocks http://t.co/fSJRKTmXW8

— Christian Tharp, CMT (@cmtstockcoach) March 26, 2015

Jason Napodano, Zacks Biotech Analyst (@JNapodano)

A chartered financial analyst, Jason Napodano does his homework. He’s worked as an equity analyst for Zacks for more than a decade. Before that, he worked at a biotech company called TechLab. He pays attention to the details and shares tons of information in his tweets.

$NUOT exited 2014 with ~$16M in cash. They burned $4M in the Q4. I'm thinking they burn $7M in Q1+Q2'15. So not as desperate as I thought.

— Jason Napodano, CFA (@JNapodano) April 1, 2015

Brad Loncar, Biotech Investor (@bradloncar)

Brad Loncar is an individual buy and hold investor who focuses on innovative companies with good management. He follows the news closely and tweets about it often.

Dan Welch joins $RARE's board. Hey, good to have someone with M&A experience, right. http://t.co/j8Ueo3kSr9

— Brad Loncar (@bradloncar) April 13, 2015

Juan Pedro Rodriguez Serrate, Reserach Analyst for Chimera Research Group (@JPZaragoza1)

Juan Pedro Serrate has both a doctoral degree in veterinary science and a master’s degree in biotechnology. He works as a research analyst for Chimera Research Group, a firm that focuses specifically on the biotechnology and pharmaceutical sectors. Serrate often tweets about daily trading action.

Tigenix: USPTO grants patent. Stock up 9%. Phase III data from European trial expected in Q3 2015. $TIG

— Juan P. Serrate, DVM (@JPZaragoza1) April 8, 2015

Vikram Khanna, Biotech Investor (@VikramKhanna_)

Follow Vikram Khanna for a lot of useful charts and graphs, as well as some interesting trading ideas.

$CDTX ~$225M pre-clin anti-infective play- Jeff Stein- Investment proposition, Pipeline and milestones pic.twitter.com/3w151RegRE

— Vikram Khanna (@VikramKhanna_) April 13, 2015

Thug Biotech Analyst, Chairman of the Twitter Biotech Board (@Thug_BioAnalyst)

Fans of the Wu-Tang Financial Twitter account will probably enjoy this one as well. Follow for amusing biotech commentary and retweets of other experts.

$ATHX shareholders be like... pic.twitter.com/biGkHP8JWD

— Thug Biotech Analyst (@Thug_BioAnalyst) April 8, 2015